试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-03
Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix
编号:NCT03644342登记状态:提前终止企业 / 申办者:Michelle S Ludwig
药物 / 成分:Nirapaib
登记的停止原因(原文):A recent change in treatment landscape may make study futile
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
编号:NCT04747470登记状态:提前终止企业 / 申办者:Gilead Sciences
药物 / 成分:GS-3583、Zimberelimab、Cisplatin、Carboplatin
登记的停止原因(原文):Sponsor decision to prematurely discontinue the study, following an internal safety assessment of the molecule, GS-3583.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-30
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
编号:NCT04036461登记状态:提前终止企业 / 申办者:Celgene
药物 / 成分:CC-99712、BMS-986405
登记的停止原因(原文):Slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-30
Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19
编号:NCT04389450登记状态:提前终止企业 / 申办者:Pluristem Ltd.
药物 / 成分:PLX-PAD、Placebo
登记的停止原因(原文):The decision to bring the Study to early clinical readout came in response to COVID-19's evolution as a disease, and the significant changes in the standard of care, leading to an increase in the severity of conditions of the intubated patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-30
Non-Opioid Pain Medications After Intracapsular Adenotonsillectomy
编号:NCT04791761登记状态:提前终止企业 / 申办者:David Chi, MD
药物 / 成分:Oxycodone、Ibuprofen、Acetaminophen、Opioid disposal pouch
登记的停止原因(原文):slow recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-30
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in ABO-Incompatible Liver Transplantation
编号:NCT05666453登记状态:提前终止企业 / 申办者:SK Plasma Co., Ltd.
药物 / 成分:LIV-GAMMA SN Inj.、No intervention
登记的停止原因(原文):Change of Clincal Development Plan
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-29
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
编号:NCT00321698登记状态:提前终止企业 / 申办者:OHSU Knight Cancer Institute
药物 / 成分:Intensity-Modulated Radiation Therapy (IMRT)、Docetaxel+IMRT
登记的停止原因(原文):Funding withdrawal
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-29
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
编号:NCT01284348登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:Sotatercept 15 mg、Sotatercept 30 mg
登记的停止原因(原文):Persistent low enrollment made study continuation no longer feasible
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-29
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
编号:NCT02964507登记状态:提前终止企业 / 申办者:GlaxoSmithKline
药物 / 成分:GSK525762、Placebo、Fulvestrant
登记的停止原因(原文):This study has been terminated due to meeting protocol defined futility.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-29
Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy
编号:NCT03831113登记状态:提前终止企业 / 申办者:Steve N. Caritis, MD
药物 / 成分:Magnitude Group、Frequency Group
登记的停止原因(原文):poor recruitment
查看官方原始记录 ↗